Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print   

Monday 06 November, 2006

XTL Biopharm Ltd

XTL Biopharmaceuticals Announces Corporate Pres...


  XTL Biopharmaceuticals Announces Corporate Presentations to be Held Today,   
                           Monday, November 6, 2006                            

            -- Rodman & Renshaw 8th Annual Healthcare Conference --            
          -- CIBC World Markets 17th Annual Healthcare Conference --           

NEW YORK, NEW YORK, November 6, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's
Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 8th
Annual Healthcare Conference and the CIBC World Markets 17th Annual Healthcare
Conference. Both presentations will be held today, as follows:

Rodman & Renshaw 8th Annual Healthcare Conference - 10:15 am EST at the New
York Palace Hotel in New York City. A live webcast of Mr. Bentsur's
presentation will be available at http://www.wsw.com/webcast/rrshq10/xtl.ln/. 
An archived version of the webcast will be available following the conclusion of
the live presentation.

CIBC World Markets 17th Annual Healthcare Conference - 12:55 pm EST at the
Waldorf Astoria Hotel in New York City. A live webcast of Mr. Bentsur's
presentation will be available at http://www.veracast.com/webcasts/cibcwm/
healthcare06/54109276.cfm. An archived version of the webcast will be available 
following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL
is also developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical trials in
patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule inhibitors.  XTL
also has an active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on the NASDAQ,
London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960

                                                                               
                                  Page 2 of 1                                  


                                                                                                                                                                                                                               

a d v e r t i s e m e n t